-
公开(公告)号:US20120088738A1
公开(公告)日:2012-04-12
申请号:US13263324
申请日:2010-04-07
IPC分类号: A61K31/69 , A61P29/00 , A61P37/00 , A61P19/02 , A61P25/22 , A61P25/00 , A61P9/00 , A61P25/06 , C07F5/02 , A61P25/24
CPC分类号: C07F5/025
摘要: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
摘要翻译: 本文提供式(I)化合物或其药学上可接受的盐,溶剂合物或前药或其混合物,其中Z1,Z2,X1,X2,X3,R1,R2,R3,R4,m和n如本文所定义。 还提供了药学上可接受的组合物,其包括式I化合物和药学上可接受的赋形剂。 还提供了用于治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的本发明的化合物或组合物。
-
公开(公告)号:US08957049B2
公开(公告)日:2015-02-17
申请号:US12901421
申请日:2010-10-08
申请人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
摘要翻译: 本发明提供了由式(I),(II),(III),(IV),(V)或(VI)或其子类中的任何一种包含的化合物及其药学上可接受的组合物。 本发明还提供了通过施用治疗有效量的化合物或组合物来治疗FAAH介导的疾病,病症或病症的方法,所述化合物或组合物包含式(I),(II),(III),(IV), (Ⅴ)或(Ⅵ)或其子代的药物给予有需要的患者。 另外,本发明提供了通过施用治疗有效量的包含式(I),(II),(III),(IV),(V)或((IV))的化合物的化合物或组合物来抑制FAAH的方法, VI)或其子集合。
-
公开(公告)号:US08541581B2
公开(公告)日:2013-09-24
申请号:US13263324
申请日:2010-04-07
IPC分类号: C07F5/02
CPC分类号: C07F5/025
摘要: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
摘要翻译: 本文提供式(I)化合物或其药学上可接受的盐,溶剂合物或前药或其混合物,其中Z1,Z2,X1,X2,X3,R1,R2,R3,R4,m和n如本文所定义。 还提供了药学上可接受的组合物,其包括式I化合物和药学上可接受的赋形剂。 还提供了用于治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的本发明的化合物或组合物。
-
公开(公告)号:US08329675B2
公开(公告)日:2012-12-11
申请号:US13049779
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号:US20110224171A1
公开(公告)日:2011-09-15
申请号:US13049779
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/69 , A61P29/00 , A61P37/00 , A61P25/24 , A61P25/02 , A61P25/00 , A61P27/06 , A61P9/00 , A61P25/06
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
公开(公告)号:US20110034437A1
公开(公告)日:2011-02-10
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/55 , C07D261/20 , A61K31/42 , A61K31/438 , C07D498/10 , A61P25/00 , A61P3/00 , A61P9/00 , A61P1/08 , A61P25/28 , A61P25/30 , A61P25/20 , A61P3/04
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US08927551B2
公开(公告)日:2015-01-06
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/424 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D403/10 , C07D401/10 , C07D417/04 , C07D417/14 , C07D413/14 , C07D261/04
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US08349814B2
公开(公告)日:2013-01-08
申请号:US13049785
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
-
公开(公告)号:US20110172186A1
公开(公告)日:2011-07-14
申请号:US12901421
申请日:2010-10-08
申请人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
摘要翻译: 本发明提供了由式(I),(II),(III),(IV),(V)或(VI)或其子类中的任何一种包含的化合物及其药学上可接受的组合物。 本发明还提供了通过施用治疗有效量的化合物或组合物来治疗FAAH介导的疾病,病症或病症的方法,所述化合物或组合物包含式(I),(II),(III),(IV), (Ⅴ)或(Ⅵ)或其子代的药物给予有需要的患者。 另外,本发明提供了通过施用治疗有效量的包含式(I),(II),(III),(IV),(V)或((IV))的化合物的化合物或组合物来抑制FAAH的方法, VI)或其子集合。
-
公开(公告)号:US07947663B2
公开(公告)日:2011-05-24
申请号:US11870130
申请日:2007-10-10
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
摘要翻译: 本发明提供由式(I),(II)或(III)包含的化合物及其药物组合物。 本发明还提供了通过向患者施用治疗有效量的所提供的式(I),(II)或(III)化合物或其药物组合物来治疗FAAH介导的疾病,病症或病症的方法。 需要它。 此外,本发明提供了通过向有需要的患者施用治疗有效量的式(I),(II)或(III)化合物或其药物组合物来抑制患者的FAAH的方法。
-
-
-
-
-
-
-
-
-